Milestone Pharmaceuticals (MIST) Short-term Investments (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Short-term Investments came in at $112.9 million in Q1 2026, up 938.35% YoY from $10.9 million in Q1 2025, and up 243.02% on a QoQ basis from $32.9 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Short-term Investments (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Short-term Investments data on file, last reported at $112.9 million in Q1 2026.
- Quarterly Short-term Investments rose 938.35% year-over-year to $112.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.9 million (up 938.35% YoY) and the FY2025 annual result came in at $32.9 million, down 25.87% from the prior year.
- Short-term Investments grew to $112.9 million in Q1 2026, from $32.9 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $112.9 million in Q1 2026 to a low of $918000.0 in Q2 2025.
- A 5-year average of $45.8 million and a median of $44.4 million in 2024 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2025 — Short-term Investments plunged 98.69% — and 2026, when it soared 938.35%.
- Tracing MIST's Short-term Investments over 5 years: stood at $56.9 million in 2022, then slipped by 8.26% to $52.2 million in 2023, then fell by 14.94% to $44.4 million in 2024, then decreased by 25.87% to $32.9 million in 2025, then surged by 243.02% to $112.9 million in 2026.
- The last three Short-term Investments figures came in at $112.9 million (Q1 2026), $32.9 million (Q4 2025), and $35.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 900,000.00 |
| Mar 31, 2026 | 112.90 Mn |
| Dec 31, 2025 | 32.91 Mn |
| Sep 30, 2025 | 35.90 Mn |
| Jun 30, 2025 | 918,000.00 |
| Mar 31, 2025 | 10.87 Mn |
| Dec 31, 2024 | 44.40 Mn |
| Sep 30, 2024 | 63.62 Mn |
| Jun 30, 2024 | 69.99 Mn |
| Mar 31, 2024 | 79.35 Mn |
| Dec 31, 2023 | 52.20 Mn |
| Sep 30, 2023 | 65.87 Mn |
| Jun 30, 2023 | 55.00 Mn |
| Mar 31, 2023 | 27.00 Mn |
| Dec 31, 2022 | 56.90 Mn |
| Sep 30, 2022 | 39.95 Mn |
| Jun 30, 2022 | 23.00 Mn |
| Mar 31, 2022 | 8.00 Mn |
| Sep 30, 2021 | 15.00 Mn |
| Jun 30, 2021 | 38.00 Mn |